my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
23-12-2010: Domainex Ltd has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex’s proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries. The competition was organized by One Nucleus, the membership organisation for international life science and healthcare companies, in order to recognise UK biotech successes.
Domainex currently supports a number of drug discovery consortia: for example, working with Professor Alan Ashworth’s group at Breakthrough Breast Cancer at the Institute of Cancer Research to develop a novel breast cancer drug and with Professor Clive Robinson’s group at St George’s University of London to invent a new treatment for asthma. In both cases, Domainex helped the groups to secure Wellcome Trust SDDI funding, and has subsequently provided medicinal and computational chemistry to facilitate their drug discovery, with the aim of nominating candidate drugs by the end of the program.
Eddy Littler, CEO of Domainex said “Domainex offers high-quality and efficient drug discovery services to the global biotechnology and pharma marketplaces. We have also supported a number of drug discovery funding applications to organisations such as The Wellcome Trust, The MRC, DTRA and the Technology Strategy Board, and we will continue to do so. We are currently investigating a number of potential future collaborations with leading academic groups wishing to enter translational research. Organisations interested in translational research with validated targets in diseases of medical need should contact us to discuss the opportunities .”
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program
Horizon Discovery Ltd announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a n ... more
UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target
UCB and Domainex Ltd have jointly published the results of a collaboration in the field of cancer drug discovery. Working together, the two companies have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known ... more
Domainex to Invest in its Drug Discovery Services and Internal Oncology Pipeline in 2011
Domainex Ltd has announced plans to significantly expand its medicinal chemistry and biology capabilities in 2011. The expansion will involve relocation to larger laboratories in Cambridge and investment in new technologies that will enhance its current service offering. This will allow Dom ... more
Domainex uses unique and proprietary technologies to resolve common bottlenecks facing the pharmaceutical and biotechnology industries in the post-genomic era. Major discovery 'gaps' exist between the vast amount of genomic information that is now available, the accessibility of the corresp ... more
One Nucleus signs agreement with Bionow to expand access to One Nucleus preferred suppliers
One Nucleus announced that an agreement has been signed with Bionow for their Premium Members to have access to the One Nucleus Preferred Suppliers through the One Nucleus Purchasing Consortium Scheme. This agreement took effect on 1 January 2011. The One Nucleus Purchasing Consortium has ... more
Domainex Wins Genesis Award for its Work in Supporting Translational Research
Domainex Ltd has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex’s proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and ph ... more
One Nucleus announces new director
One Nucleus announced the appointment of Dr Alan Palmer as a Director. Alan is co-founder and currently Chief Scientific Officer for MS Therapeutics Ltd and has 30 years’ experience in the biotechnology sector in roles spanning academia, research and industry. Alan has very close ties with ... more
One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, at the heart of Europe’s largest life science and healthcare cluster. Our mission is to maximise the global competitiveness of our members. Establishe ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
